Compare LEG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | SNDX |
|---|---|---|
| Founded | 1883 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2016 |
| Metric | LEG | SNDX |
|---|---|---|
| Price | $11.26 | $20.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.00 | ★ $36.92 |
| AVG Volume (30 Days) | 2.2M | ★ 2.4M |
| Earning Date | 10-27-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $4,172,899,999.00 | $111,304,000.00 |
| Revenue This Year | N/A | $620.14 |
| Revenue Next Year | N/A | $115.42 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | ★ 595.65 |
| 52 Week Low | $6.48 | $8.58 |
| 52 Week High | $12.30 | $20.59 |
| Indicator | LEG | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 69.27 |
| Support Level | $11.26 | $18.36 |
| Resistance Level | $12.03 | $20.20 |
| Average True Range (ATR) | 0.38 | 0.98 |
| MACD | 0.23 | 0.15 |
| Stochastic Oscillator | 77.00 | 92.43 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.